Journal
BLOOD
Volume 132, Issue 26, Pages 2707-2721Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-04-846220
Keywords
-
Categories
Funding
- Cancer Australia/Cure Cancer Australia Foundation [1124096]
- Gordon and Jessie Gilmour Leukaemia Research Trust
- National Health and Medical Research Council (NHMRC) [1064569, 1025494]
- MPN Research Foundation/MPN Alliance Australia
- German Cancer Aid [111743]
- NHMRC [1042934, 1102589, 1139787, 1139811]
- Translational Cancer Research Network of the Cancer Institute of NSW
- NSW Pathology
- National Health and Medical Research Council of Australia [1139787, 1139811, 1064569, 1102589] Funding Source: NHMRC
Ask authors/readers for more resources
Myeloproliferative neoplasms (MPNs) are a group of blood cancers that arise following the sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells (HSPCs). We identify mutational cooperation between Jak2V617F expression and Dnmt3a loss that drives progression from early-stage polycythemia vera to advanced myelofibrosis. Using in vivo, clustered regularly interspaced short palindromic repeats (CRISPR) with CRISPR-associated protein 9 (Cas9) disruption of Dnmt3a in Jak2V617F knockin HSPC, we show that Dnmt3a loss blocks the accumulation of erythroid elements and causes fibrotic infiltration within the bone marrow and spleen. Transcriptional analysis and integration with human data sets identified a core DNMT3A-driven gene-expression program shared across multiple models and contexts of Dnmt3a loss. Aberrant self-renewal and inflammatory signaling were seen in Dnmt3a(-/-) Jak2V617F HSPC, driven by increased chromatin accessibility at enhancer elements. These findings identify oncogenic cooperativity between Jak2V617F-driven MPN and Dnmt3a loss, leading to activation of HSPC enhancer-driven inflammatory signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available